

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	6,758,600	6,855,500	6,938,600	7,012,000
Prediabetes	1,793,600	1,879,300	1,959,000	1,982,400
Diagnosed diabetes	531,600	638,700	726,700	793,000
Undiagnosed diabetes	184,500	210,600	227,400	235,000
Total with diabetes (diagnosed and undiagnosed)	716,100	849,300	954,100	1,028,100
Complications:				
Visual impairment	87,200	101,700	112,300	119,000
Renal failure	1,270	1,470	1,610	1,700
Leg amputations	1,100	1,210	1,270	1,280
Annual deaths attributable to diabetes	5,720	6,570	7,100	7,330
Total annual cost (2015 dollars)	\$9.4 B	\$11.0 B	\$12.4 B	\$13.3 B
Annual medical costs	\$7.0 B	\$8.1 B	\$9.1 B	\$9.8 B
Annual nonmedical costs	\$2.4 B	\$2.9 B	\$3.3 B	\$3.5 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	1,025,400	1,159,800	1,317,900	1,463,100
Prediabetes	523,000	591,500	672,100	746,200
Diagnosed diabetes	193,800	219,200	249,100	276,500
Undiagnosed diabetes	71,800	81,200	92,300	102,400
Total with diabetes (diagnosed and undiagnosed)	265,600	300,400	341,300	378,900
Complications:				
Visual impairment	36,300	39,900	44,200	47,800
Renal failure	600	650	720	770
Leg amputations	450	470	490	510
Annual deaths attributable to diabetes	3,950	4,400	4,610	4,620
Total annual cost (2015 dollars)	\$3.4 B	\$3.8 B	\$4.4 B	\$4.8 B
Annual medical costs	\$3.2 B	\$3.6 B	\$4.1 B	\$4.5 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.3 B	\$0.3 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.